<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946867</url>
  </required_header>
  <id_info>
    <org_study_id>NBTXR3-102</org_study_id>
    <secondary_id>ID RCB: 2013-A00706-39</secondary_id>
    <nct_id>NCT01946867</nct_id>
  </id_info>
  <brief_title>NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx</brief_title>
  <official_title>A Phase I Dose-Escalation/Dose Expansion Study Of NBTXR3 Activated By Intensity Modulated Radiation Therapy In Patients With Locally Advanced Squamous Cell Carcinoma Of The Oral Cavity Or Oropharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanobiotix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanobiotix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cancers of the oral cavity represent 30% of head and neck carcinomas in the&#xD;
      western world. The oropharynx is the posterior continuation of the oral cavity and connects&#xD;
      with the nasopharynx (above) and laryngopharynx (below). It is also a frequent site of&#xD;
      primary head and neck cancers. These structures play a crucial role in swallowing, breath and&#xD;
      speech. Locally advanced oropharyngeal cancers can obstruct the air flow or infiltrate&#xD;
      muscles or nerves, which significantly disturb local functions. The incidence of Head and&#xD;
      Neck Squamous Cell Cancer in patients older 65 years is high, 47% occurred in this population&#xD;
      as recorded by the Surveillance, Epidemiology, and End Results registries in the United&#xD;
      States. Regarding the therapeutic strategies, the association of radiotherapy with&#xD;
      chemotherapy or biologics has demonstrated significant improvement of outcomes with the&#xD;
      drawback of higher toxicity, or as demonstrated by 2 meta-analyses, without survival&#xD;
      improvement in older patients. NBTXR3 and radiation therapy may increase the cancer cell&#xD;
      killing and complete tumor shrinkage allowing a definitive treatment and preservation of&#xD;
      local structures and functions in patients older 65 years, who cannot receive cisplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive a single administration of NBTXR3 on day 1,as an intratumor injection,&#xD;
      followed by Intensity Modulated Radiation Therapy starting 24 hours later (Day 2), and up to&#xD;
      completion of 7 weeks, i.e. 70 Grays, 2Grays/fraction. Patients whose tumor has completely&#xD;
      shrunk will be followed for the post-radiotherapy evaluation up to the End of Treatment&#xD;
      visit. Those patients whose tumor has not shrunk more than 50% of the baseline size, will&#xD;
      stop the radiotherapy and may have a salvage tumor surgery. Then, all patients will be&#xD;
      followed every 8 weeks, for the safety evaluation and cancer disease status until the end of&#xD;
      the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2014</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study consists of two parts: Dose Escalation and Dose Expansion. This phase I is an open-label non-randomized, dose-escalation/dose expansion study of safety and tolerability evaluation of NBTXR3, administered as an intratumoral implantation by injection, activated by intensity modulated radiation therapy (IMRT), in patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation: Incidence of DLTs and determination of the Recommended Phase 2 Dose</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of early DLTs (early adverse effects related to NBTXR3, as an intratumor injection, activated by IMRT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation: Determination of the Recommended Phase 2 Dose</measure>
    <time_frame>12 months</time_frame>
    <description>The recommended Phase II dose (RD) of NBTXR3 administered as intratumor injection, activated by Intensity Modulated Radiation Therapy (IMRT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion: Overall Response Rate</measure>
    <time_frame>12-24 months</time_frame>
    <description>The Objective Response Rate (ORR) of the primary tumor, by imaging according to RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion: Complete Response Rate</measure>
    <time_frame>12-24 months</time_frame>
    <description>The Complete Response Rate (CRR) of the primary tumor, by imaging according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Objective Response Rate (ORR) of the primary tumor</measure>
    <time_frame>12-24 months</time_frame>
    <description>The Objective Response Rate (ORR) of the primary tumor, by imaging according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Complete Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The Complete Response Rate (CRR) of the primary tumor, by imaging according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Local Progression Free Survival</measure>
    <time_frame>12-24 months</time_frame>
    <description>Local Progression Free Survival (LPFS) defined as any recurrence at the site of the primary tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Progression Free Survival</measure>
    <time_frame>12-24 months</time_frame>
    <description>Progression Free Survival (PFS) defined as the time to any progression at the site of the primary tumor, in regional lymph nodes and/or distant metastasis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>NBTXR3 IntraTumoral injection (IT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intratumor injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NBTXR3 activated by IMRT</intervention_name>
    <arm_group_label>NBTXR3 IntraTumoral injection (IT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients aged ≥ 70 years old, or&#xD;
&#xD;
          -  Patients aged ≥ 65 years old and &lt; 70 years old who are unable to receive cisplatin,&#xD;
             or&#xD;
&#xD;
          -  Patients who have contraindication to cisplatin or that are intolerant to cisplatin or&#xD;
             cetuximab or that cannot receive the combination of chemoradiation, regardless the age&#xD;
&#xD;
          -  Histologically or cytologically confirmed squamous cell carcinoma (SCC) of the oral&#xD;
             cavity or oropharynx&#xD;
&#xD;
          -  T3 or T4 primary tumor or Stage III or IVA according to AJCC guidelines (8th Edition,&#xD;
             2018)&#xD;
&#xD;
          -  No evidence of distant metastatic disease, as determined by a negative PET scan or CT&#xD;
             scan&#xD;
&#xD;
          -  Clinically eligible for intratumor implantation by injection&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 70&#xD;
&#xD;
          -  Adequate function of Bone marrow:&#xD;
&#xD;
               -  White Blood Cell (WBC) &gt; 3.0 x 10^9/L&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; or = 1.0 x 10^9/L&#xD;
&#xD;
               -  Platelet count &gt; or = 100 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin &gt; or = 9.0 g/dL&#xD;
&#xD;
          -  Adequate function of Kidney:&#xD;
&#xD;
             o Creatinine &lt; or = 3.0 x ULN or creatinine clearance &gt; or = 30 mL/min/1.73m²&#xD;
&#xD;
          -  Adequate function of the liver:&#xD;
&#xD;
               -  AST &lt; or = 5 x ULN&#xD;
&#xD;
               -  ALT &lt; or = 5 x ULN&#xD;
&#xD;
               -  Bilirubin &lt; or = 1.5 x ULN&#xD;
&#xD;
          -  Negative pregnancy test ≤ 7 days of NBTXR3 injection in all females of child-bearing&#xD;
             potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Written Informed Consent not obtained, signed and dated&#xD;
&#xD;
          -  Prior radiotherapy to any area within the planned radiotherapy field&#xD;
&#xD;
          -  Tumor-related dyspnea&#xD;
&#xD;
          -  Tumor ulceration which implies vascular risk&#xD;
&#xD;
          -  Non measurable disease as defined by RECIST criteria&#xD;
&#xD;
          -  History of stroke, CABG, or significant blockage of carotid arteries or coronary&#xD;
             arteries or current blockage of coronary or carotid arteries equal to or in excess of&#xD;
             50% blockage&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             severe infection, symptomatic congestive heart failure, acute coronary syndrome, etc.&#xD;
&#xD;
          -  Medical history of life-threatening ventricular arrhythmia&#xD;
&#xD;
          -  Prior or concurrent non-head and neck malignancies, excluding adequately treated basal&#xD;
             or squamous cell cancer of the skin, and in situ cervical cancer, and any other cancer&#xD;
             from which the subject has been cancer free for 5 years&#xD;
&#xD;
          -  Concurrent treatment with any other anticancer therapy, including chemotherapy,&#xD;
             immunotherapy, targeted therapy, gene therapy, or patients planning to receive these&#xD;
             treatments during the study&#xD;
&#xD;
          -  Patients unable to comply with scheduled visits, treatment plans, laboratory tests,&#xD;
             and other study procedures or those with severe psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements&#xD;
&#xD;
          -  Patients participating in another clinical investigation at the time of signature of&#xD;
             the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe LE TOURNEAU, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie PIQUET, PhD</last_name>
    <phone>+33 (0)1 81 92 03 19</phone>
    <email>emilie.piquet@nanobiotix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsa BORGHI, MD</last_name>
    <phone>+33 (0)1 40 26 26 87</phone>
    <email>elsa.borghi@nanobiotix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen FLORESCU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier LIEM, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien SALAS, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles POISSONNET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe LE TOURNEAU, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck JEGOUX, Pr.,MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>France NGUYEN THANH VAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hungarian Defense Forces Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna PAPAI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltan TAKACSI-NAGY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. M. Skłodowskiej- Curie, Oddział w Gliwicach</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof SKLADOWSKI, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej W Kielcach</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slawomir OKLA, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej im. Św. Jana z Dukli</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof KUPISZ, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NU-MED, Provita Prolife</name>
      <address>
        <city>Tomaszów Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek FIJUTH, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nu-Med Centrum Diagnostyki I Terapii Onkologicznej Zamość Spółka Z Ograniczoną Odpowiedzialnością</name>
      <address>
        <city>Zamość</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael MASLOWSKI, MD-PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miren SANZ TABERNA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena GARRALDA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Fundación Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor MORENO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano CALVO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Regional de Malaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge CONTRERAS, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral cavity Cancer</keyword>
  <keyword>Oropharynx Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

